The aim of this case–control study is to evaluate the clinical and biochemical efficiency of Inositol versus Metformin in polycystic ovary syndrome.
The 128 patients who completed the study were divided into group A, which included 62 patients prescribed myo-inositol+D-chiro-inositol, two tabs per day, and group B, which included 66 patients prescribed Metformin 1500 mg per day for 3 months. Then, both groups were followed up for 3 months after the end of the treatment period. All patients underwent the following: baseline vaginal ultrasound, BMI and weight evaluation, Anti mullerian hormones (AMH) evaluation, serum progesterone, and Homeostasis Model of Assessment-Insulin Resistance (HOMA-IR), and were evaluated according to clinical and biochemical outcomes.
Spontaneous menstruation and spontaneous pregnancy rate were significantly higher in group A than in group B: 46.7 and 11.2% in the Inositol group compared with 13.6 and 3.0% in the Metformin group. In terms of weight loss, the difference between both groups was significant in favor of the Inositol group. A significant difference was also detected in terms of a higher progesterone level in group A, whereas AMH and HOMA-IR showed insignificant differences in both groups.
Myo-inositol+D-chiro-inositol showed significantly better results in terms of weight reduction, resumption of spontaneous ovulation, and spontaneous pregnancy than Metformin in polycystic ovary syndrome patients. However, the effects of both drugs were comparable in decreasing either AMH or HOMA-IR.
aDepartment of Obstetrics & Gynecology, Ain Shams University Hospital, Cairo, Egypt
bHabib Medical Center, Abu Dhabi
cDubai Fertility Center, DFOG, Dubai, UAE
Correspondence to Amr Mohamed S. Abdel Hamid, MD, Department of Obstetrics & Gynecology, Ain Shams University Hospital, Cairo, Egypt Tel: +971 532 8835; e-mail: email@example.com
Received January 23, 2015
Accepted February 20, 2015